ProQR Therapeutics (NASDAQ:PRQR) Upgraded by Citigroup to Buy Rating

Citigroup upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a neutral rating to a buy rating in a report issued on Monday morning, MarketBeat.com reports. The brokerage currently has $4.00 price target on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. JMP Securities reiterated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.17.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.85 on Monday. The company has a 50 day moving average of $2.29 and a 200-day moving average of $2.62. The firm has a market cap of $151.11 million, a P/E ratio of -5.78 and a beta of 0.24. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its holdings in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. OneDigital Investment Advisors LLC increased its stake in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the period. Ballentine Partners LLC acquired a new position in ProQR Therapeutics in the 4th quarter valued at approximately $61,000. Altium Capital Management LLC acquired a new position in ProQR Therapeutics in the 4th quarter valued at approximately $1,524,000. Finally, Affinity Asset Advisors LLC acquired a new position in ProQR Therapeutics in the 4th quarter valued at approximately $7,486,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).